Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $4.03B | $3.87B | +3.98% |
Gross Profit | $2.39B | $2.33B | +2.80% |
Net Income | $869.19M | $863.14M | +0.70% |
EPS (Basic) | $42.17 | $40.67 | +3.69% |
EPS (Diluted) | $42.05 | $40.48 | +3.88% |
R&D Expense | $199.37M | $189.36M | +5.29% |
SG&A Expense | $998.31M | $936.3M | +6.62% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $3.71B | $3.24B | +14.59% |
Current Assets | $1.36B | $1.19B | +14.14% |
Total Liabilities | $3.74B | $3.37B | +10.97% |
Current Liabilities | $1.2B | $1.17B | +2.56% |
Stockholders' Equity | $-23.64M | $-126.89M | +81.37% |
Long-Term Debt | $2.09B | $1.83B | +14.03% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $955.77M | $968.35M | -1.30% |
Investing Cash Flow | $-193.87M | $-119.46M | -62.29% |
Financing Cash Flow | $-755.17M | $-855.98M | +11.78% |
Share Buybacks | $800M | $850M | -5.88% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Gross Margin | 59.4% | 60.1% | -0.68% |
Net Margin | 21.6% | — | — |
ROE | -3677.4% | — | — |
ROA | 23.4% | — | — |
Current Ratio | $1.137 | — | — |
Debt to Equity | $-158.076 | — | — |
MTD's financial performance in 2025 showed modest revenue growth and improved equity position despite declining cash flows and persistent debt challenges.
MTD achieved a 4.0% increase in revenue, driven by strong sales in key markets.
Source: Source: 10-K Income Statement
Despite a 6.6% increase in SG&A expenses, MTD maintained a stable gross margin, indicating effective cost management.
Source: Source: 10-K Income Statement
The company's stockholders' equity improved significantly by 81.4%, though it remains negative, indicating ongoing financial restructuring efforts.
Source: Source: 10-K Balance Sheet
MTD's long-term debt increased by 14.0%, which could pressure future cash flows and limit financial flexibility.
Source: Source: 10-K Balance Sheet
Unlock 2 more detailed risk analysis
Upgrade to unlockOther companies in Life Sciences Tools & Services